Brand Name
Raxibacumab
View Brand InformationFDA approval date: December 14, 2012
Classification: Anthrax Protective Antigen-directed Antibody
Form: Injection
What is Raxibacumab?
Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment